Cisplatin and Campath drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cisplatin (cisplatin) and Campath (alemtuzumab). Common drug interactions include bone density decreased among females and pulmonary alveolar haemorrhage among males.

The phase IV clinical study analyzes what interactions people have when they take Cisplatin and Campath. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Cisplatin?

Cisplatin has active ingredients of cisplatin. It is often used in chemotherapy. eHealthMe is studying from 92,837 Cisplatin users. Check the latest studies of Cisplatin.

What is Campath?

Campath has active ingredients of alemtuzumab. eHealthMe is studying from 4,909 Campath users. Check the latest studies of Campath.

On Jul, 14, 2026

13 people who take Cisplatin and Campath together, and have interactions are studied.

Cisplatin and Campath drug interactions.

What are the common drug interactions of Cisplatin and Campath, by gender? *:

female:

Bone density decreased
Bone loss
Confusional state
Disease progression
Epstein-barr virus infection
Grand mal convulsion (a type of generalized seizure that affects the entire brain)
Granuloma (a small area of inflammation due to tissue injury)
Headache (pain in head)
Multiple fractures
Mycosis fungoides refractory (lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin unmanageable)

male:

Pulmonary alveolar haemorrhage (acute bleeding)
Hepatic failure (liver failure)
Disease progression
Hepatitis b
Acute graft versus host disease in intestine (acute complication in intestine following an allogeneic tissue/blood transplant)
Arteriospasm coronary (spasm of the large- or medium-sized coronary arteries)
Hypotension (abnormally low blood pressure)
Pulmonary embolism (blockage of the main artery of the lung)
Interstitial lung disease
Neutropenia (an abnormally low number of neutrophils)

What are the common drug interactions of Cisplatin and Campath, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Disease progression

40-49:

Hepatitis b
Bone density decreased
Bone loss
Confusional state
Epstein-barr virus infection
Grand mal convulsion (a type of generalized seizure that affects the entire brain)
Granuloma (a small area of inflammation due to tissue injury)
Headache (pain in head)
Multiple fractures
Mycosis fungoides refractory (lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin unmanageable)

50-59:

Pulmonary alveolar haemorrhage (acute bleeding)
Interstitial lung disease
Neutropenia (an abnormally low number of neutrophils)
Respiratory failure (inadequate gas exchange by the respiratory system)
Disease progression

60+:

Acute graft versus host disease in intestine (acute complication in intestine following an allogeneic tissue/blood transplant)
Arteriospasm coronary (spasm of the large- or medium-sized coronary arteries)
Hypotension (abnormally low blood pressure)
Pulmonary embolism (blockage of the main artery of the lung)

What are the existing conditions these people have? *

Peripheral T-Cell Lymphoma Unspecified Recurrent (peripheral t-cell cancer unspecified recurrent): 7 people, 53.85%
Peripheral T-Cell Lymphoma Unspecified (peripheral t-cell cancer unspecified): 2 people, 15.38%
Mycosis Fungoides (lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin): 1 person, 7.69%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 1 person, 7.69%
Large Granular Lymphocytosis (increased number of large granular white blood cells): 1 person, 7.69%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 7.69%
Dehydration (dryness resulting from the removal of water): 1 person, 7.69%
Adult T-Cell Lymphoma/leukaemia (cancer of the immune system's own t-cells): 1 person, 7.69%
Acute Graft Versus Host Disease In Intestine (acute complication in intestine following an allogeneic tissue/blood transplant): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Cisplatin and Campath?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously